CEO at SIRION, Christian Thirion, joins InProTher as a Board Member
InProTher is pleased to welcome Christian O. Thirion, Ph.D., who has joined the Board of Directors in February 2020.
Christian is the founder and CEO of SIRION Biotech GmbH, a company that InProTher recently entered into a partnership with. At SIRION, he has held multiple leadership positions and has been responsible for the scientific direction and strategic planning for the company.
Prior to founding SIRION in 2005, Christian was a postdoctoral fellow at the Department of gene therapy at Universitätsklinikum Ulm and led a team for neuromuscular disorders research at the Universitätsklinikum der Ludwig-Maximilians-Universität München.
“I’m equally honored and excited to become a part of InProTher’s journey as a Board Member. A lot of great things are happening in the company at the moment, and with the clinical development beginning soon, it’s only going to be more exciting,” says Christian Thirion.
With his extensive research and knowledge within gene therapy and viral vectors, Thirion is foreseen to be an invaluable asset in InProTher.
“In order for us to unlock the full potential of immunotherapy in cancer treatment, we need to gather the best of the best. Christian Thirion’s knowledge is a major asset in setting this team,” says Peter J. Holst, CSO and interim CEO at InProTher.
Christian holds a Ph.D. in Biochemistry and a diploma in Chemistry, both from Ludwig-Maximilians-Universität München.